Address
Zernikelaan 8
9747AW Groningen
Netherlands
Contact
Auke van Heel+310641428952
aukevanheel@omnicin.com
Website
Download PDF
Bismocin
Bismocin an inhaled low-dose CBS therapy, enhances antibiotics to treat resistant P. aeruginosa. Safe, low-cost, and non-competitive with current care, it prevents biofilms and resistance, offering targeted, effective lung infection treatment.
Bismocin delivers targeted lung therapy, enhancing antibiotics against resistant Pseudomonas aeruginosa. It eradicates bacteria, prevents biofilm formation, and limits resistance development. As a repurposed drug, low-dose bismuth is safe, cost-effective, and simplifies development with reduced costs and timelines. Bismocin complements existing antibiotics as an add-on therapy without competing, providing an innovative and practical solution for managing resistant lung infections.
- Antimicrobial stewardship
- Infection prevention
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Validation
- Research
- Market entry
- Marketed product
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- RTI
- UTI
- STI
- BSI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
We are currently closing our €5.8 million seed round, with 2/3 of the required funds already committed. This funding will drive the development of Bismocin, our innovative therapy for resistant Pseudomonas aeruginosa lung infections.
Omnicin Therapeutics is an early-stage pharmaceutical company based in the Netherlands. The company is engaged in developing therapeutic solutions to overcome antimicrobial resistance, mainly in resistant Gram-negative pathogens. Omnicin is developing OTX003, a dry-powder inhalation formulation of low-dose colloidal bismuth subcitrate that potentiates existing antibiotics to effectively treat lung infections caused by resistant P. aeruginosa.
N.A.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!